PP2A: The achilles heal in MDS with 5q deletion

Frontiers in Oncology

Volumn 4, Issue SEP, 2014, Pages

  Sallman, David A ^a   Wei, Sheng ^a   List, Alan ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Deletion 5q; Lenalidomide; MDM2; Myelodysplastic syndrome; p53; PP2A; RPS14

Indexed keywords

CENERSEN; CYCLIN B; LENALIDOMIDE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN MDM2; PROTEIN P53; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR;

5Q- SYNDROME; ARTICLE; CELL CYCLE ARREST; CYTOTOXICITY; DISEASE COURSE; DOWN REGULATION; GENE EXPRESSION; GENE MUTATION; HUMAN; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE;

EID: 84907016891     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00264     Document Type: Article

References (61)

1. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood (1997) 89(6):2079-88. PubMed PMID: 9058730.
2. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood (2012) 120(12):2454-65. doi: 10.1182/blood-2012-03-420489. PubMed PMID: 22740453.
3. Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood (2007) 110(13):4385-95. doi: 10.1182/blood-2007-03-082404. PubMed PMID: 17726160.
4. Kulasekararaj AG, Mohamedali AM, Mufti GJ. Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes. British journal of haematology (2013) 162(5):587-605. doi: 10.1111/bjh.12435. PubMed PMID: 23869491.
5. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of point mutations in myelodysplastic syndromes. The New England journal of medicine (2011) 364(26):2496-506. doi: 10.1056/NEJMoa1013343. PubMed PMID: 21714648; PubMed Central PMCID: PMC3159042.
6. Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, et al. Validation of a prognostic model and the impact of mutations in patients with lowerrisk myelodysplastic syndromes. Journal of clinical oncology: official journal of the American Society of Clinical Oncology (2012) 30(27):3376-82. doi: 10.1200/JCO.2011.40.7379. PubMed PMID: 22869879; PubMed Central PMCID: PMC3438234.
7. Giagounidis AA, Germing U, Haase S, Hildebrandt B, Schlegelberger B, Schoch C, et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia (2004) 18(1):113- 9. doi: 10.1038/sj.leu.2403189. PubMed PMID: 14586479.
8. Kulasekararaj AG, Smith AE, Mian SA, Mohamedali AM, Krishnamurthy P, Lea NC, et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. British journal of haematology (2013) 160(5):660-72. doi: 10.1111/bjh.12203. PubMed PMID: 23297687.
9. Mallo M, Cervera J, Schanz J, Such E, Garcia-Manero G, Luno E, et al. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia (2011) 25(1):110-20. doi: 10.1038/leu.2010.231. PubMed PMID: 20882045.
10. Patnaik MM, Lasho TL, Finke CM, Knudson RA, Ketterling RP, Chen D, et al. Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients. American journal of hematology (2011) 86(5):393-8. doi: 10.1002/ajh.21984. PubMed PMID: 21523797.
11. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, et al. Efficacy of lenalidomide in myelodysplastic syndromes. The New England journal of medicine (2005) 352(6):549-57. doi: 10.1056/NEJMoa041668. PubMed PMID: 15703420.
12. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. The New England journal of medicine (2006) 355(14):1456-65. doi: 10.1056/NEJMoa061292. PubMed PMID: 17021321.
13. List AF, Bennett JM, Sekeres MA, Skikne B, Fu T, Shammo JM, et al. Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomidetreated patients with lower-risk del(5q) MDS. Leukemia (2014) 28(5):1033-40. doi: 10.1038/leu.2013.305. PubMed PMID: 24150217; PubMed Central PMCID: PMC4017258.
14. Boultwood J, Fidler C, Strickson AJ, Watkins F, Gama S, Kearney L, et al. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood (2002) 99(12):4638-41. PubMed PMID: 12036901.
15. Horrigan SK, Westbrook CA, Kim AH, Banerjee M, Stock W, Larson RA. Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval. Blood (1996) 88(7):2665-70. PubMed PMID: 8839861.
16. Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature (1974) 251(5474):437-8. PubMed PMID: 4421285.
17. Heaney ML, Golde DW. Myelodysplasia. The New England journal of medicine (1999) 340(21):1649-60. doi: 10.1056/NEJM199905273402107. PubMed PMID: 10341278.
18. Boultwood J, Pellagatti A, Cattan H, Lawrie CH, Giagounidis A, Malcovati L, et al. Gene expression profiling of CD34+ cells in patients with the 5q- syndrome. British journal of haematology (2007) 139(4):578-89. doi: 10.1111/j.1365-2141.2007.06833.x. PubMed PMID: 17916100.
19. Pellagatti A, Fernandez-Mercado M, Di Genua C, Larrayoz MJ, Killick S, Dolatshad H, et al. Whole-exome sequencing in del(5q) myelodysplastic syndromes in transformation to acute myeloid leukemia. Leukemia (2014) 28(5):1148-51. doi: 10.1038/leu.2013.381. PubMed PMID: 24365791.
20. Draptchinskaia N, Gustavsson P, Andersson B, Pettersson M, Willig TN, Dianzani I, et al. The gene encoding ribosomal protein S19 is mutated in Diamond- Blackfan anaemia. Nature genetics (1999) 21(2):169-75. doi: 10.1038/5951. PubMed PMID: 9988267.
21. Gazda HT, Zhong R, Long L, Niewiadomska E, Lipton JM, Ploszynska A, et al. RNA and protein evidence for haplo-insufficiency in Diamond-Blackfan anaemia patients with RPS19 mutations. British journal of haematology (2004) 127(1):105-13. doi: 10.1111/j.1365-2141.2004.05152.x. PubMed PMID: 15384984.
22. Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature (2008) 451(7176):335-9. doi: 10.1038/nature06494. PubMed PMID: 18202658; PubMed Central PMCID: PMC3771855.
23. Dutt S, Narla A, Lin K, Mullally A, Abayasekara N, Megerdichian C, et al. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood (2011) 117(9):2567-76. doi: 10.1182/blood- 2010-07-295238. PubMed PMID: 21068437; PubMed Central PMCID: PMC3062351.
24. Fumagalli S, Di Cara A, Neb-Gulati A, Natt F, Schwemberger S, Hall J, et al. Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. Nature cell biology (2009) 11(4):501-8. doi: 10.1038/ncb1858. PubMed PMID: 19287375.
25. Lohrum MA, Ludwig RL, Kubbutat MH, Hanlon M, Vousden KH. Regulation of HDM2 activity by the ribosomal protein L11. Cancer cell (2003) 3(6):577-87. PubMed PMID: 12842086.
26. Shangary S, Wang S. Small-molecule inhibitors of the MDM2-p53 proteinprotein interaction to reactivate p53 function: a novel approach for cancer therapy. Annual review of pharmacology and toxicology (2009) 49:223-41. doi: 10.1146/annurev.pharmtox.48.113006.094723. PubMed PMID: 18834305; PubMed Central PMCID: PMC2676449.
27. Peller S, Frenkel J, Lapidot T, Kahn J, Rahimi-Levene N, Yona R, et al. The onset of p53-dependent apoptosis plays a role in terminal differentiation of human normoblasts. Oncogene (2003) 22(30):4648-55. doi: 10.1038/sj.onc.1206541. PubMed PMID: 12879009.
28. Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nature medicine (2010) 16(1):49-58. doi: 10.1038/nm.2054. PubMed PMID: 19898489.
29. Oliva EN, Cuzzola M, Aloe Spiriti MA, Poloni A, Lagana C, Rigolino C, et al. Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study. Annals of hematology (2013) 92(1):25-32. doi: 10.1007/s00277-012-1569-0. PubMed PMID: 22983750.
30. Kumar MS, Narla A, Nonami A, Mullally A, Dimitrova N, Ball B, et al. Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome. Blood (2011) 118(17):4666-73. doi: 10.1182/blood-2010-12-324715. PubMed PMID: 21873545; PubMed Central PMCID: PMC3208282.
31. Wei S, Chen X, Rocha K, Epling-Burnette PK, Djeu JY, Liu Q, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proceedings of the National Academy of Sciences of the United States of America (2009) 106(31):12974-9. doi: 10.1073/pnas.0811267106. PubMed PMID: 19470455; PubMed Central PMCID: PMC2722346.
32. Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. The Biochemical journal (2001) 353(Pt 3):417-39. PubMed PMID: 11171037; PubMed Central PMCID: PMC1221586.
33. Sartor H, Ehlert F, Grzeschik KH, Muller R, Adolph S. Assignment of two human cell cycle genes, CDC25C and CCNB1, to 5q31 and 5q12, respectively. Genomics (1992) 13(3):911-2. PubMed PMID: 1386342.
34. Margolis SS, Perry JA, Forester CM, Nutt LK, Guo Y, Jardim MJ, et al. Role for the PP2A/B56delta phosphatase in regulating 14-3-3 release from Cdc25 to control mitosis. Cell (2006) 127(4):759-73. doi: 10.1016/j.cell.2006.10.035. PubMed PMID: 17110335; PubMed Central PMCID: PMC2789796.
35. Wilker EW, Grant RA, Artim SC, Yaffe MB. A structural basis for 14-3-3sigma functional specificity. The Journal of biological chemistry (2005) 280(19):18891-8. doi: 10.1074/jbc.M500982200. PubMed PMID: 15731107.
36. Wei S, Chen X, McGraw K, Zhang L, Komrokji R, Clark J, et al. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene (2013) 32(9):1110-20. doi: 10.1038/onc.2012.139. PubMed PMID: 22525275; PubMed Central PMCID: PMC3751397.
37. Westermarck J, Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends in molecular medicine (2008) 14(4):152-60. doi: 10.1016/j.molmed.2008.02.001. PubMed PMID: 18329957.
38. Mi J, Bolesta E, Brautigan DL, Larner JM. PP2A regulates ionizing radiationinduced apoptosis through Ser46 phosphorylation of p53. Molecular cancer therapeutics (2009) 8(1):135-40. doi: 10.1158/1535-7163.MCT-08-0457. PubMed PMID: 19139122.
39. Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nature cell biology (2001) 3(3):245-52. doi: 10.1038/35060032. PubMed PMID: 11231573.
40. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung MC. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nature cell biology (2001) 3(11):973-82. doi: 10.1038/ncb1101-973. PubMed PMID: 11715018.
41. Bally C, Ades L, Renneville A, Mozziconacci MJ, Preudhomme C, DeThe´ H, et al. P-006 Prognostic value of TP53 gene mutations in higher-risk MDS treated with azacitidine (AZA). Leukemia Research 37:S25. doi: 10.1016/S0145-2126(13)70055-9.
42. Mallo M, del Rey M, Iba´ñez M, Calasanz MJ, Arenillas L, Larra´yoz MJ, et al. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. British journal of haematology (2013) 162(1):74-86. doi: 10.1111/bjh.12354.
43. Jadersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, Gohring G, et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. Journal of clinical oncology: official journal of the American Society of Clinical Oncology (2011) 29(15):1971-9. doi: 10.1200/JCO.2010.31.8576. PubMed PMID: 21519010.
44. Saft L, Karimi M, Ghaderi M, Matolcsy A, Mufti GJ, Kulasekararaj A, et al. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). Haematologica (2014). doi: 10.3324/haematol.2013.098103. PubMed PMID: 24682512.
45. Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusiondependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood (2011) 118(14):3765-76. doi: 10.1182/blood-2011-01-330126. PubMed PMID: 21753188.
46. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability--an evolving hallmark of cancer. Nature reviews Molecular cell biology (2010) 11(3):220-8. doi: 10.1038/nrm2858. PubMed PMID: 20177397.
47. List AF, Estes M, Williams A, Sekharam M, Ozawa U, Gao G, et al. Lenalidomide (CC-5013; Revlimid(R)) Promotes Erythropoiesis in Myelodysplastic Syndromes (MDS) by CD45 Protein Tyrosine Phosphatase (PTP) Inhibition. ASH Annual Meeting Abstracts (2006) 108(11):1360-.
48. Park DM, Li J, Okamoto H, Akeju O, Kim SH, Lubensky I, et al. N-CoR pathway targeting induces glioblastoma derived cancer stem cell differentiation. Cell cycle (2007) 6(4):467-70. PubMed PMID: 17312396.
49. Hart ME, Chamberlin AR, Walkom C, Sakoff JA, McCluskey A. Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity. Bioorganic & medicinal chemistry letters (2004) 14(8):1969-73. doi: 10.1016/j.bmcl.2004.01.093. PubMed PMID: 15050639.
50. Lu J, Kovach JS, Johnson F, Chiang J, Hodes R, Lonser R, et al. Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms. Proceedings of the National Academy of Sciences of the United States of America (2009) 106(28):11697-702. doi: 10.1073/pnas.0905930106. PubMed PMID: 19564615; PubMed Central PMCID: PMC2710674.
51. Zhuang Z, Lu J, Lonser R, Kovach JS. Enhancement of cancer chemotherapy by simultaneously altering cell cycle progression and DNA-damage defenses through global modification of the serine/threonine phospho-proteome. Cell cycle (2009) 8(20):3303-6. PubMed PMID: 19806030.
52. Zhang C, Peng Y, Wang F, Tan X, Liu N, Fan S, et al. A synthetic cantharidin analog for the enhancement of doxorubicin suppression of stem cell-derived aggressive sarcoma. Biomaterials (2010) 31(36):9535-43. doi: 10.1016/j.biomaterials.2010.08.059. PubMed PMID: 20875681.
53. Lu J, Zhuang Z, Song DK, Mehta GU, Ikejiri B, Mushlin H, et al. The effect of a PP2A inhibitor on the nuclear receptor corepressor pathway in glioma. Journal of neurosurgery (2010) 113(2):225-33. doi: 10.3171/2009.11.JNS091272. PubMed PMID: 20001590.
54. Vincent M. Chung ASM, John Kovach. A phase 1 study of a novel inhibitor of protein phosphatase 2A alone and with docetaxel. Journal of clinical oncology: official journal of the American Society of Clinical Oncology (2014) 32(5s):suppl; abstr TPS2636.
55. Uttamsingh V, Gallegos R, Cheng C, Aslanian A, Liu JF, Tung R, et al. Abstract 3357: CTP-221, a deuterated S-enantiomer of lenalidomide, is greatly stabilized to epimerization and results in a more desirable pharmacokinetic profile than racemic lenalidomide. Cancer Research (2013) 73(8 Supplement):3357. doi: 10.1158/1538- 7445.am2013-3357.
56. Bishop MR, Iversen PL, Bayever E, Sharp JG, Greiner TC, Copple BL, et al. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. Journal of clinical oncology: official journal of the American Society of Clinical Oncology (1996) 14(4):1320-6. PubMed PMID: 8648390.
57. Cortes J, Kantarjian H, Ball ED, Dipersio J, Kolitz JE, Fernandez HF, et al. Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer (2012) 118(2):418-27. doi: 10.1002/cncr.26292. PubMed PMID: 21717444.
58. Lanasa MC, Davis PH, Datto M, Li Z, Gockerman JP, Moore JO, et al. Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia. Leukemia and lymphoma (2012) 53(2):218-24. doi: 10.3109/10428194.2011.610012. PubMed PMID: 21827374.
59. Caceres G, McGraw K, Yip BH, Pellagatti A, Johnson J, Zhang L, et al. TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients. Proceedings of the National Academy of Sciences of the United States of America (2013) 110(40):16127-32. doi: 10.1073/pnas.1311055110. PubMed PMID: 24043769; PubMed Central PMCID: PMC3791697.
60. Woll PS, Kjallquist U, Chowdhury O, Doolittle H, Wedge DC, Thongjuea S, et al. Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo. Cancer cell (2014). doi: 10.1016/j.ccr.2014.03.036. PubMed PMID: 24835589.
61. Tehranchi R, Woll PS, Anderson K, Buza-Vidas N, Mizukami T, Mead AJ, et al. Persistent malignant stem cells in del(5q) myelodysplasia in remission. The New England journal of medicine (2010) 363(11):1025-37. doi: 10.1056/NEJMoa0912228. PubMed PMID: 20825315.